K. H. Rahn

1.5k total citations
56 papers, 1.2k citations indexed

About

K. H. Rahn is a scholar working on Cardiology and Cardiovascular Medicine, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, K. H. Rahn has authored 56 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 12 papers in Psychiatry and Mental health and 9 papers in Molecular Biology. Recurrent topics in K. H. Rahn's work include Blood Pressure and Hypertension Studies (11 papers), Neurological Complications and Syndromes (8 papers) and Pharmacological Effects and Toxicity Studies (7 papers). K. H. Rahn is often cited by papers focused on Blood Pressure and Hypertension Studies (11 papers), Neurological Complications and Syndromes (8 papers) and Pharmacological Effects and Toxicity Studies (7 papers). K. H. Rahn collaborates with scholars based in Germany, Netherlands and Italy. K. H. Rahn's co-authors include Michael Barenbrock, Martin Hausberg, Markus Kosch, Klaus Kisters, Helge Hohage, Giuseppe Mancia, Alberto Zanchetti, M. Gene Bond, John L. Reid and Lothar Eckes and has published in prestigious journals such as Hypertension, European Heart Journal and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

K. H. Rahn

56 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. H. Rahn Germany 18 603 231 172 151 132 56 1.2k
John A. Opsahl United States 17 457 0.8× 206 0.9× 197 1.1× 228 1.5× 129 1.0× 48 1.1k
N Pozet France 20 275 0.5× 199 0.9× 176 1.0× 259 1.7× 93 0.7× 86 1.1k
H.-H. Neumayer Germany 18 223 0.4× 204 0.9× 286 1.7× 326 2.2× 63 0.5× 43 1.3k
H. Weihprecht United States 16 474 0.8× 135 0.6× 218 1.3× 284 1.9× 216 1.6× 22 1.2k
Przemysław Rutkowski Poland 20 291 0.5× 154 0.7× 131 0.8× 335 2.2× 241 1.8× 76 1.1k
Hajime Nakahama Japan 21 582 1.0× 308 1.3× 287 1.7× 330 2.2× 220 1.7× 85 1.4k
Gerjan Navis Netherlands 22 311 0.5× 190 0.8× 226 1.3× 480 3.2× 270 2.0× 60 1.4k
Carlos Campo Spain 20 642 1.1× 184 0.8× 141 0.8× 324 2.1× 213 1.6× 75 1.1k
B L Kasiske United States 13 180 0.3× 168 0.7× 456 2.7× 264 1.7× 191 1.4× 16 1.3k
Tsutomu Sanaka Japan 19 196 0.3× 117 0.5× 345 2.0× 464 3.1× 194 1.5× 104 1.4k

Countries citing papers authored by K. H. Rahn

Since Specialization
Citations

This map shows the geographic impact of K. H. Rahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. H. Rahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. H. Rahn more than expected).

Fields of papers citing papers by K. H. Rahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. H. Rahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. H. Rahn. The network helps show where K. H. Rahn may publish in the future.

Co-authorship network of co-authors of K. H. Rahn

This figure shows the co-authorship network connecting the top 25 collaborators of K. H. Rahn. A scholar is included among the top collaborators of K. H. Rahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. H. Rahn. K. H. Rahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kosch, Markus, Michael Barenbrock, Barbara Suwelack, et al.. (2003). Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases. 41(5). 1088–1096. 24 indexed citations
2.
Rahn, K. H.. (2003). Aktuelle Interventionsstudien zur Hochdrucktherapie und ihr Einfluss auf Therapieempfehlungen*. Medizinische Klinik. 98(12). 771–775. 4 indexed citations
3.
Barenbrock, Michael, et al.. (2002). Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. Journal of Hypertension. 20(1). 79–84. 104 indexed citations
4.
Hausberg, Martin, Markus Kosch, Michael Barenbrock, et al.. (2001). A novel assay for determination of diadenosine polyphosphates in human platelets: studies in normotensive subjects and in patients with essential hypertension. Journal of Hypertension. 19(2). 237–245. 14 indexed citations
5.
Zanchetti, Alberto, M. Gene Bond, Michael Hennig, et al.. (1998). Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension. 16(7). 949–961. 254 indexed citations
6.
Khattab, Mahmoud M., et al.. (1998). Effects of Diadenosine Polyphosphates on Systemic and Regional Hemodynamics in Anesthetized Rats. Kidney & Blood Pressure Research. 21(1). 42–49. 17 indexed citations
7.
Kaufmann, Christoph C., et al.. (1994). Albuminuria in HIV-Infected Patients. AIDS Research and Human Retroviruses. 10(6). 717–720. 6 indexed citations
8.
Tepel, Martin, Gregor Theilmeier, J. Bachmann, et al.. (1994). Increased cytosolic sodium and reduced Na,K-ATPase activity in transgenic rats.. Hypertension. 23(1_supplement). I198–202. 9 indexed citations
9.
Heidenreich, Stefan, Detlef Lang, Martin Tepel, & K. H. Rahn. (1994). Monocyte activation for enhanced tumour necrosis factor-α and interleukin 6 production during chronic renal allograft rejection. Transplant Immunology. 2(1). 35–40. 28 indexed citations
10.
Crepaldi, Gaetano, Achille C. Pessina, & K. H. Rahn. (1993). Effects of different antihypertensive agents on the overall cardiovascular risk profile. Journal of Hypertension. 11(Supplement 6). S41–S41. 2 indexed citations
11.
Crepaldi, Gaetano, Achille C. Pessina, & K. H. Rahn. (1993). Effects of different antihypertensive agents on the overall cardiovascular risk profile. Journal of Hypertension. 11. S41–S41. 1 indexed citations
12.
Spieker, Claus, Walter Zidek, H. Vetter, & K. H. Rahn. (1991). Ambulatory 24-H Blood Pressure Monitoring in Essential Hypertensives Treated with the Angiotensin-Converting Enzyme Inhibitor Ramipril. Journal of International Medical Research. 19(1). 39–43. 3 indexed citations
13.
Spieker, Claus, et al.. (1991). Cardiovascular Side Effects After Renal Allograft Rejection Therapy with Orthoclone. Journal of Cardiovascular Pharmacology. 18. S79–S81. 3 indexed citations
14.
Spieker, Claus, Walter Zidek, & K. H. Rahn. (1991). Na+, K+-ATPase Inhibition and Intracellular Electrolyte Content in Essential and Secondary Hypertensionn. American Journal of Hypertension. 4(4_Pt_1). 309–314. 5 indexed citations
15.
Bortel, L.M.A.B. Van, et al.. (1990). The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients. European Journal of Clinical Pharmacology. 39(1). S39–S40. 2 indexed citations
16.
Baumgart, Peter, et al.. (1989). Nocturnal hypertension in renal failure, haemodialysis and after renal transplantation. Journal of Hypertension. 7(6). S70–71. 32 indexed citations
17.
Rahn, K. H.. (1987). Antihypertensive Compounds with Combined Actions. Journal of Cardiovascular Pharmacology. 10. S18–S22. 8 indexed citations
18.
Mooy, J., et al.. (1985). Pharmacokinetics of verapamil in patients with renal failure. European Journal of Clinical Pharmacology. 28(4). 405–410. 30 indexed citations
19.
20.
Rahn, K. H.. (1965). Ein Vergleich der ?-adrenolytischen und der chinidinartigen Wirkungen von 1-(3-Methylphenoxy)-2-hydroxy-3-isopropylamino-propan. Naunyn-Schmiedeberg s Archives of Pharmacology. 251(2). 128–129. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John A. Opsahl Breakdown of academic impact, for papers by N Pozet Breakdown of academic impact, for papers by H.-H. Neumayer Breakdown of academic impact, for papers by H. Weihprecht Breakdown of academic impact, for papers by Przemysław Rutkowski Breakdown of academic impact, for papers by Hajime Nakahama Breakdown of academic impact, for papers by Gerjan Navis Breakdown of academic impact, for papers by Carlos Campo Breakdown of academic impact, for papers by B L Kasiske Breakdown of academic impact, for papers by Tsutomu Sanaka
Rankless by CCL
2026